Moxonidine
As of the edition of 20 October 2026, Moxonidine is a small molecule: marketed, first approved in 1994 (FR); acts on NISCH.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1997
- Kind
- Small molecule
- Brand name
- Physiotens
- First approved
- 19 September 1994 (FR)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Viatris; 2 holders in all
- Registered trials
- 15, 3 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Nervous system; Bones, joints and muscles; Hormones; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NISCH | Nischarin | Q9Y2I1 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 1 |
| Phase 1 | 3 | 0 | 2 | 1 |
| Phase 2 | 1 | 0 | 1 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 8 | 4 | 0 | 1 |
| All trials | 15 |